Last update 02 Nov 2024
Velmupressin
Last update 02 Nov 2024
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms velmupressin, FE 201836, FE-201836 + [1] |
Target |
Mechanism AVPR2 agonists(Vasopressin V2 receptor agonists) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC42H60ClN11O8S2 |
InChIKeyVXHQBKSIDHVNIG-ZABOXFJKSA-N |
CAS Registry1647119-61-6 |
Gene Sequence
Sequence Code 526207387
Source: *****
Related
3
Clinical Trials associated with VelmupressinA Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults
An open-label, 3 doses fixed sequence trial investigating safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral and intravenous administrations of FE 201836 in elderly subjects - FE 201836 Safety, PK, PD Study
A double-blind, placebo controlled, randomised, parallel group study with an open-label cross-over part, investigating safety, tolerability, pharmacokinetics, and pharmacodynamics after single ascending oral doses and a single intravenous dose of the vasopressin V2-receptor agonist FE 201836 - FE 201836 SAD and cross-over study
100 Clinical Results associated with Velmupressin
Login to view more data
100 Translational Medicine associated with Velmupressin
Login to view more data
100 Patents (Medical) associated with Velmupressin
Login to view more data
100 Deals associated with Velmupressin
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Nocturia | Phase 2 | US | 27 Jul 2017 | |
| Nocturia | Phase 2 | BE | 27 Jul 2017 | |
| Nocturia | Phase 2 | CA | 27 Jul 2017 | |
| Nocturia | Phase 2 | CZ | 27 Jul 2017 | |
| Nocturia | Phase 2 | DE | 27 Jul 2017 | |
| Nocturia | Phase 2 | HU | 27 Jul 2017 | |
| Nocturia | Phase 2 | PL | 27 Jul 2017 | |
| Polyuria | Phase 2 | US | 27 Jul 2017 | |
| Polyuria | Phase 2 | BE | 27 Jul 2017 | |
| Polyuria | Phase 2 | CA | 27 Jul 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free